Keymed Biosciences posts strong H1 2026 growth, with core product Kangyueda sales up 132% YoY, underscoring momentum in China's biotech sector
Executive summary: Keymed Biosciences announced H1 2026 results with revenue of RMB617 million and core product Kangyueda sales up 132% year-on-year to RMB393 million. Shows strong growth in a key product, indicating market acceptance and potential for sustained revenue expansion in China's biotech sector.
Who is involved: Keymed Biosciences (HKEX:02162), its management, investors, and analysts covering Hong Kong-listed healthcare stocks.
Likely next: The company may provide full-year 2026 guidance, consider capacity expansion, or pursue additional pipeline developments; investors will watch for any upcoming clinical updates or partnership announcements.
The company reported total revenue of RMB617 million for the six months ended June 30, 2026, driven by a surge in sales of its flagship Kangyueda product, which rose to RMB393 million. This performance reflects robust demand and successful commercialization in a competitive domestic market. While the results are encouraging, they also raise expectations for sustained growth and further pipeline advancement in the second half of the year.
Timeline
- — China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"? (PR Newswire)
- — Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy (PR Newswire)
- — Keymed Biosciences Announces 2026 H1 Results and Business Updates (PR Newswire)
Analysis — what this means
Sectors affected
- Chinese biotechnology
- oncology pharmaceuticals
- healthcare manufacturing
Sources
- Keymed Biosciences Announces 2026 H1 Results and Business Updates — PR Newswire
- China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"? — PR Newswire
- Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy — PR Newswire
Related cases
- Europe’s wind power capacity surged 30% YoY to 8.8 GW in H1 2026, signaling accelerating renewable investment and potential pressure on fossil fuel markets
- Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by its Kangyueda product
- Keymed Biosciences reports H1 2026 revenue of 617 million RMB driven by core product Kangyueda
- Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by flagship Kangyueda sales
- Classys approaches 50,000 global device sales as expanded product lineup drives 29% YoY export growth in first half 2026
- Microcredit boom is squeezing family budgets, with 3.8 million loans up 46% YoY despite experts warning it fails to ease debt